In Cheshire, a pharmaceutical manufacturer producing over-the-counter medicines and health supplements was struggling with soaring energy bills.
Precision controlled laboratories, sterilisation systems, and 24-hour production lines created some of the highest energy demands in the sector.
By 2024, monthly electricity costs averaged £50,000, and the finance director admitted these costs were beginning to erode profitability even as demand for products grew.
“We had invested heavily in quality assurance and R&D,” the FD explained, “but every gain was being eaten away by rising energy bills. We needed a way to stabilise costs without restricting investment in growth.”
The company’s modern facility featured an expansive, flat, reinforced roof – an ideal site for solar.
Initial estimates showed the roof could host a system capable of generating over 65% of daily electricity demand. But the directors initially dismissed the idea, assuming the upfront capital required would compete with budgets reserved for critical R&D and compliance.
The breakthrough came with an asset-financed solution.
Instead of paying millions upfront, the pharmaceutical firm entered a structured finance agreement.
The repayments were locked in below their current grid costs, making the project cash-positive from day one.
Installation was carefully scheduled around regulatory requirements, ensuring zero disruption to production. Within four months, the solar system was fully operational.
Electricity bills dropped from £50,000 to around £20,000, with finance repayments of £25,000. The net effect: a £5,000 monthly saving immediately, alongside protection from volatile energy markets.
Over a 20-year horizon – once the finance was settled – projections showed more than £7 million saved, as well as a reduction of 1,500 tonnes of CO₂ emissions.
But beyond the impressive numbers, the solar installation provided a reputational lift in a sector where sustainability is increasingly important.
Major pharmaceutical buyers and retail chains are under pressure to ensure their supply chains cut emissions.
By demonstrating real action, the company gained an edge in procurement negotiations.
Within six months, they secured a multi-year supply deal with a leading UK pharmacy chain, with sustainability cited as a factor in the decision.
Internally, the solar project was embraced as a symbol of innovation.
The managing director reflected:
“We’ve always been about science and progress. Adding solar wasn’t just financial sense – it aligned perfectly with our values and strengthened how customers and staff view us.”
For finance directors across pharmaceuticals, the lesson is clear:
Solar is not a side project. It is a strategic tool for financial stability, customer trust, and long-term resilience.
By turning unused rooftop space into a power station, this manufacturer reduced energy bills and positioned itself as a sustainability leader in a regulated, competitive market.
